Theravance Biopharma, Inc. Proceeds from Sale of Available-for-sale Securities
Theravance Biopharma, Inc. (TBPH) reported Proceeds from Sale of Available-for-sale Securities of $0 for the 12-month period ending 2017-12-31, per its 10-K filed 2018-02-28.
Discontinued › Cash Flow › Investing Activities
us-gaap:ProceedsFromSaleOfAvailableForSaleSecurities · last filed 2018-02-28
- Theravance Biopharma, Inc. proceeds from sale of available-for-sale securities for fiscal 2017 was $0.00.
- Theravance Biopharma, Inc. proceeds from sale of available-for-sale securities for fiscal 2016 was $0.00.
- Theravance Biopharma, Inc. proceeds from sale of available-for-sale securities for fiscal 2015 was $0.00, a 100.00% decline from fiscal 2014.
- Theravance Biopharma, Inc. proceeds from sale of available-for-sale securities for fiscal 2014 was $900.00K.
| Period end | Proceeds from Sale of Available-for-sale Securities 12 month |
|---|---|
| 2017-12-31 | $0.00 10-K · filed 2018-02-28 |
| 2016-12-31 | $0.00 10-K · filed 2018-02-28 |
| 2015-12-31 | $0.00 10-K · filed 2018-02-28 |
| 2014-12-31 | $900.00K 10-K · filed 2017-03-01 |
| 2013-12-31 | $0.00 10-K · filed 2016-03-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |